[Note: This case study was originally published in 2009. Download a PDF or read the case study here.]
In resource-restricted settings, nevirapine is a critical drug for preventing mother-to-child HIV prevention (PMTCT) during labor and delivery. HIV-positive mothers take a tablet early in labor and give a liquid formulation orally to the infants within 72 hours of birth. In Africa, many fewer babies than mothers receive their dose. A major obstacle has been the lack of individually packaged doses of liquid pediatric nevirapine. The large number of women who give birth at home should be given such doses during antenatal clinic visits. A collaboration among PATH, the United States Agency for International Development (USAID), nevirapine producer Boehringer Ingelheim, the Elizabeth Glaser Pediatric AIDS Foundation and the Kenya Ministry of Health set out to develop a simple nevirapine delivery system for newborns.
- Reducing rates of mother-to-child HIV transmission in Africa, where many babies are born at home, requires treatments that can be administered easily by the new mother or her birthing assistant, outside of a hospital or health care facility.
- Simple technical changes in packaging can increase access and usage of needed medication.
- Collaborations between corporate drug developers and nonprofit organizations combine the dual need for research and advocacy to achieve these technical changes.